Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
danny.wright@ndm.ox.ac.uk

Research groups

Oxford Vaccine Group

Daniel Wright

Senior Postdoctoral Researcher

Recent publications

Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222).

Belij-Rammerstorfer S. et al, (2025), EBioMedicine, 118

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.

Costa Clemens SA. et al, (2025), Mayo Clin Proc Innov Qual Outcomes, 9

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Venkatraman N. et al, (2025), Lancet Microbe, 6

Rift Valley fever seroprevalence and risk factors among human populations in Uganda's cattle corridor: a cross-sectional study.

Anywaine Z. et al, (2025), BMJ Public Health, 3

Adenoviral vaccines—Infectious disease

Bliss CM. et al, (2025), 573 - 642

More publications